
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Chris Hatwig, MS, FASHP of Apexus discusses what health-system pharmacists need to know about the potential for HRSA audits to review 340B program compliance requirements.
Chris Hatwig, MS, FASHP of Apexus discusses what health-system pharmacists need to know about the potential for HRSA audits to review 340B program compliance requirements.
This video was shot at ASHP's Summer Meetings and Exposition in Denver in June 2015.






